Objective To investigate the effect of Yinlai Decoction(YD)on the microstructure of colon,and activity of D-lactic acid(DLA)and diamine oxidase(DAO)in serum of pneumonia mice model fed with high-calorie and high-prote...Objective To investigate the effect of Yinlai Decoction(YD)on the microstructure of colon,and activity of D-lactic acid(DLA)and diamine oxidase(DAO)in serum of pneumonia mice model fed with high-calorie and high-protein diet(HCD).Methods Sixty male Kunming mice were randomly divided into 6 groups by the random number table method:normal control,pneumonia,HCD,HCD with pneumonia(HCD-P),YD(229.2 mg/mL),and dexamethasone(15.63 mg/mL)groups,with 10 in each group.HCD mice were fed with 52%milk solution by gavage.Pneumonia mice was modeled with lipopolysaccharide inhalation and was fed by gavage with either the corresponding therapeutic drugs or saline water,twice daily,for 3 days.After hematoxylin-eosin staining,the changes in the colon structure were observed under light microscopy and transmission electron microscope,respectively.Enzyme-linked immunosorbent assay was used to detect the protein levels of DLA and DAO in the serum of mice.Results The colonic mucosal structure and ultrastructure of mice in the normal control group were clear and intact.The colonic mucosal goblet cells in the pneumonia group tended to increase,and the size of the microvilli varied.In the HCD-P group,the mucosal goblet cells showed a marked increase in size with increased secretory activity.Loose mucosal epithelial connections were also observed,as shown by widened intercellular gaps with short sparse microvilli.These pathological changes of intestinal mucosa were significantly reduced in mouse models with YD treatment,while there was no significant improvement after dexamethasone treatment.The serum DLA level was significantly higher in the pneumonia,HCD,and HCD-P groups as compared with the normal control group(P<0.05).Serum DLA was significantly lower in the YD group than HCD-P group(P<0.05).Moreover,serum DLA level significantly increased in the dexamethasone group as compared with the YD group(P<0.01).There was no statistical significance in the serum level of DAO among groups(P>0.05).Conclusions YD can protect function of intestinal mucosa by improving the tissue morphology of intestinal mucosa and maintaining integrity of cell connections and microvilli structure,thereby reducing permeability of intestinal mucosa to regulate the serum levels of DLA in mice.展开更多
Chiral materials with the same atomic compositions exhibit different chemical,physical,and biological properties because of their distinct spatial structures.Herein,a chiral strategy was proposed to develop poly(lacti...Chiral materials with the same atomic compositions exhibit different chemical,physical,and biological properties because of their distinct spatial structures.Herein,a chiral strategy was proposed to develop poly(lactic acid)(PLA)nanoparticle as an efficient nanoadjuvant to activate adaptive anticancer immunity.Two chiral nanovaccines were prepared by directly mixing amino-terminated PLA(PLLA-NH2 or PDLA-NH2)with the model protein antigen ovalbumin(OVA).After being injected into mice subcutaneously,both nanovaccines efficiently migrated to the lymph nodes to initiate the sequential anticancer immune responses.Compared with the PLLA nanovaccine(PLLA-OVA),the PDLA one(PDLA-OVA)contributed to more robust dendritic cell(DC)maturation,antigen presentation,and T lymphocyte activation.In addition to the activation of cellular immunity,PDLA-OVA also triggered a more vigorous activation of humoral immunity,which induced the production of more anti-OVA immunoglobulin G(IgG)than PLLA-OVA.When used as prophylactic or therapeutic nanovaccine toward murine melanoma models,PDLA-OVA triggered more potent adaptive anticancer immune responses that more effectively inhibited the cancer genesis and progression,indicating the significant potential of immunologically effective PDLA nanoadjuvant in cancer immunotherapy.展开更多
目的探讨温肾健脾固肠方联合督脉灸在腹泻型肠易激综合征患者(脾肾阳虚证)治疗中的应用价值。方法所有腹泻型肠易激综合征患者(脾肾阳虚证)均于2022年3月至2023年6月在我院就诊并随机分组,两组均81例,对照组采用西医常规治疗,观察组采...目的探讨温肾健脾固肠方联合督脉灸在腹泻型肠易激综合征患者(脾肾阳虚证)治疗中的应用价值。方法所有腹泻型肠易激综合征患者(脾肾阳虚证)均于2022年3月至2023年6月在我院就诊并随机分组,两组均81例,对照组采用西医常规治疗,观察组采用温肾健脾固肠方及督脉灸治疗,治疗4周后比较疗效。结果治疗后两组血清白细胞介素-6(interleukin-6,IL-6)、脑源性神经生长因子(brain-derived neuotrophyic factor,BDNF)、D-乳酸、神经肽Y(neuropeptide Y,NPY)、胃泌素(gastrin,GAS)、5-羟色胺(5-hydroxytryptamine,5-HT)低于对照组,白细胞介素-10(interleukin-10,IL-10)更高,观察组改善更显著,差异具统计学意义(P<0.05);治疗后两组汉密尔顿抑郁量表(Hamilton depression scale,HAMD)、中医总症状积分更低,肠易激综合征生活质量评分(quality of life score for irritable bowel syndrome,IBS-QOL评分)更高,观察组改善更显著(P<0.05);观察组总有效率92.59%(75/81),高于对照组的82.72%(67/81),差异具统计学意义(P<0.05)。结论对于腹泻型肠易激综合征患者(脾肾阳虚证),采用温肾健脾固肠方联合督脉灸治疗更有助于减轻炎症反应,调控神经递质,改善肠黏膜屏障功能,促进病情好转,进而提高临床疗效。展开更多
This study aims to augment the D-lactic acid biosynthetic capacity of Lactobacillus delbrueckii subsp.bulgaricus ATCC 11842 through random mutagenesis.The mutant strain,Mut_N23,developed through synergistic applicatio...This study aims to augment the D-lactic acid biosynthetic capacity of Lactobacillus delbrueckii subsp.bulgaricus ATCC 11842 through random mutagenesis.The mutant strain,Mut_N23,developed through synergistic application of ultraviolet(UV)irradiation and chemical mutagenesis using N-methyl-N′-nitro-N-nitrosoguanidine(NTG),exhibited 97%increase in D-lactic acid production and 37%enhancement in glucose uptake rate at flask level.Mut_N23 consistently produced optically pure D-lactic acid across seven generations,efficiently metabolizing lactose and sucrose to yield 4.47 g L^(−1) and 3.38 g L^(−1) of D-lactic acid,respectively.Optimal conditions identified through One-Factor-At-a-Time(OFAT),and Response Surface Methodology(RSM)facilitated maximum D-lactic acid concentration of 7.88 g L^(−1)(300%increase)from lactose-MRS(deMan Rogosa Sharpe)with specific productivity of 0.110 g g^(−1) h^(−1).When lactose was replaced with whey permeate as an application,4.89 g L^(−1)(140%increase)of D-lactic acid was obtained,with specific productivity of 0.066 g g^(−1) h^(−1) in lab-scale bioreactor setups,achieving 99.09%optical purity.Transcriptomics and enzymatic activity analyses substantiated enhanced performance of Mut_N23 signifying beneficial random mutations.Furthermore,characterization of purified D-lactic acid derived from whey permeate using Fourier Transform Infrared(FTIR)spectroscopy and proton Nuclear Magnetic Resonance(NMR)spectroscopy demonstrated parity with commercially available standards.This study highlights Mut_N23’s potential for efficient D-lactic acid production exploiting a spectrum of carbon sources,providing a foundation for future metabolic engineering to enhance biosynthetic productivity.展开更多
基金Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(No.ZYYCXTD-C-202006)。
文摘Objective To investigate the effect of Yinlai Decoction(YD)on the microstructure of colon,and activity of D-lactic acid(DLA)and diamine oxidase(DAO)in serum of pneumonia mice model fed with high-calorie and high-protein diet(HCD).Methods Sixty male Kunming mice were randomly divided into 6 groups by the random number table method:normal control,pneumonia,HCD,HCD with pneumonia(HCD-P),YD(229.2 mg/mL),and dexamethasone(15.63 mg/mL)groups,with 10 in each group.HCD mice were fed with 52%milk solution by gavage.Pneumonia mice was modeled with lipopolysaccharide inhalation and was fed by gavage with either the corresponding therapeutic drugs or saline water,twice daily,for 3 days.After hematoxylin-eosin staining,the changes in the colon structure were observed under light microscopy and transmission electron microscope,respectively.Enzyme-linked immunosorbent assay was used to detect the protein levels of DLA and DAO in the serum of mice.Results The colonic mucosal structure and ultrastructure of mice in the normal control group were clear and intact.The colonic mucosal goblet cells in the pneumonia group tended to increase,and the size of the microvilli varied.In the HCD-P group,the mucosal goblet cells showed a marked increase in size with increased secretory activity.Loose mucosal epithelial connections were also observed,as shown by widened intercellular gaps with short sparse microvilli.These pathological changes of intestinal mucosa were significantly reduced in mouse models with YD treatment,while there was no significant improvement after dexamethasone treatment.The serum DLA level was significantly higher in the pneumonia,HCD,and HCD-P groups as compared with the normal control group(P<0.05).Serum DLA was significantly lower in the YD group than HCD-P group(P<0.05).Moreover,serum DLA level significantly increased in the dexamethasone group as compared with the YD group(P<0.01).There was no statistical significance in the serum level of DAO among groups(P>0.05).Conclusions YD can protect function of intestinal mucosa by improving the tissue morphology of intestinal mucosa and maintaining integrity of cell connections and microvilli structure,thereby reducing permeability of intestinal mucosa to regulate the serum levels of DLA in mice.
基金supported by the National Natural Science Foundation of China(52273159,52273158,U21A2099,52173149,52073280,52022095,51973216,51873207,51833010)the Science and Technology Development Program of Jilin Province(20210509005RQ,20210504001GH,20200404182YY)+1 种基金the“Special Project for City-Academy Scientific and Technological Innovation Cooperation”of Changchun(21SH14)the Youth Innovation Promotion Association of Chinese Academy of Sciences(2019230)。
文摘Chiral materials with the same atomic compositions exhibit different chemical,physical,and biological properties because of their distinct spatial structures.Herein,a chiral strategy was proposed to develop poly(lactic acid)(PLA)nanoparticle as an efficient nanoadjuvant to activate adaptive anticancer immunity.Two chiral nanovaccines were prepared by directly mixing amino-terminated PLA(PLLA-NH2 or PDLA-NH2)with the model protein antigen ovalbumin(OVA).After being injected into mice subcutaneously,both nanovaccines efficiently migrated to the lymph nodes to initiate the sequential anticancer immune responses.Compared with the PLLA nanovaccine(PLLA-OVA),the PDLA one(PDLA-OVA)contributed to more robust dendritic cell(DC)maturation,antigen presentation,and T lymphocyte activation.In addition to the activation of cellular immunity,PDLA-OVA also triggered a more vigorous activation of humoral immunity,which induced the production of more anti-OVA immunoglobulin G(IgG)than PLLA-OVA.When used as prophylactic or therapeutic nanovaccine toward murine melanoma models,PDLA-OVA triggered more potent adaptive anticancer immune responses that more effectively inhibited the cancer genesis and progression,indicating the significant potential of immunologically effective PDLA nanoadjuvant in cancer immunotherapy.
文摘目的探讨温肾健脾固肠方联合督脉灸在腹泻型肠易激综合征患者(脾肾阳虚证)治疗中的应用价值。方法所有腹泻型肠易激综合征患者(脾肾阳虚证)均于2022年3月至2023年6月在我院就诊并随机分组,两组均81例,对照组采用西医常规治疗,观察组采用温肾健脾固肠方及督脉灸治疗,治疗4周后比较疗效。结果治疗后两组血清白细胞介素-6(interleukin-6,IL-6)、脑源性神经生长因子(brain-derived neuotrophyic factor,BDNF)、D-乳酸、神经肽Y(neuropeptide Y,NPY)、胃泌素(gastrin,GAS)、5-羟色胺(5-hydroxytryptamine,5-HT)低于对照组,白细胞介素-10(interleukin-10,IL-10)更高,观察组改善更显著,差异具统计学意义(P<0.05);治疗后两组汉密尔顿抑郁量表(Hamilton depression scale,HAMD)、中医总症状积分更低,肠易激综合征生活质量评分(quality of life score for irritable bowel syndrome,IBS-QOL评分)更高,观察组改善更显著(P<0.05);观察组总有效率92.59%(75/81),高于对照组的82.72%(67/81),差异具统计学意义(P<0.05)。结论对于腹泻型肠易激综合征患者(脾肾阳虚证),采用温肾健脾固肠方联合督脉灸治疗更有助于减轻炎症反应,调控神经递质,改善肠黏膜屏障功能,促进病情好转,进而提高临床疗效。
基金supported by the Department of Biotechnology(Ministry of Science and Technology,Govt.of India)via project no.BT/PR24592/NER/95/764/2017.
文摘This study aims to augment the D-lactic acid biosynthetic capacity of Lactobacillus delbrueckii subsp.bulgaricus ATCC 11842 through random mutagenesis.The mutant strain,Mut_N23,developed through synergistic application of ultraviolet(UV)irradiation and chemical mutagenesis using N-methyl-N′-nitro-N-nitrosoguanidine(NTG),exhibited 97%increase in D-lactic acid production and 37%enhancement in glucose uptake rate at flask level.Mut_N23 consistently produced optically pure D-lactic acid across seven generations,efficiently metabolizing lactose and sucrose to yield 4.47 g L^(−1) and 3.38 g L^(−1) of D-lactic acid,respectively.Optimal conditions identified through One-Factor-At-a-Time(OFAT),and Response Surface Methodology(RSM)facilitated maximum D-lactic acid concentration of 7.88 g L^(−1)(300%increase)from lactose-MRS(deMan Rogosa Sharpe)with specific productivity of 0.110 g g^(−1) h^(−1).When lactose was replaced with whey permeate as an application,4.89 g L^(−1)(140%increase)of D-lactic acid was obtained,with specific productivity of 0.066 g g^(−1) h^(−1) in lab-scale bioreactor setups,achieving 99.09%optical purity.Transcriptomics and enzymatic activity analyses substantiated enhanced performance of Mut_N23 signifying beneficial random mutations.Furthermore,characterization of purified D-lactic acid derived from whey permeate using Fourier Transform Infrared(FTIR)spectroscopy and proton Nuclear Magnetic Resonance(NMR)spectroscopy demonstrated parity with commercially available standards.This study highlights Mut_N23’s potential for efficient D-lactic acid production exploiting a spectrum of carbon sources,providing a foundation for future metabolic engineering to enhance biosynthetic productivity.
